- Stocks
- Pharma & Healthcare
- Senores Pharmaceuticals
Senores Pharmaceuticals share price
NSE: SENORESPharma & HealthcareDrug Manufacturers - General
Senores Pharmaceuticals at a glance
Senores Pharmaceuticals (NSE: SENORES) closed at ₹1,233.30 on 22 Oct 2026, up 0.35% on the day. With a market capitalisation of ₹5,680 Cr, it ranks 740th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 46.7× trailing earnings, against a return on equity of 7.4% in FY25. Over the past year the share price has risen 71.0%. Its 52-week range is ₹706.00 (23 Mar 2026) to ₹1,599.00 (24 Aug 2026); the last close is 22.9% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹180 Cr (+38.3% year on year) and net profit ₹30 Cr (+43.8%), on a consolidated basis. Promoters held 45.82% of the company as of 30 Jun 2026; 2.81% of promoter shares were pledged.
Key numbers
- Market cap
- ₹5,680 CrRank 740 on NSE
- P/E (trailing)
- 46.7×
- Price to book
- 3.35×FY25
- EPS (TTM)
- ₹28.40to Q1 FY27
- ROE
- 7.4%FY25
- ROCE
- 9.3%FY25
- Debt to equity
- 0.39FY25
- Net profit margin
- 14.6%FY25
- Book value / share
- ₹170.73FY25
- 52-week high
- ₹1,599.0024 Aug 2026
- 52-week low
- ₹706.0023 Mar 2026
- 1-year return
- +71.0%
- RSI (14-day)
- 35.8
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +0.35% | −3.7% | −11.6% | −11.4% | +71.0% |
Senores Pharmaceuticals quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹98 Cr | ₹103 Cr | ₹114 Cr | ₹130 Cr | ₹153 Cr | ₹165 Cr | ₹175 Cr | ₹180 Cr |
| Revenue YoY | — | +30.9% | −46.8% | +16,187.5% | +56.1% | +60.0% | +53.4% | +38.3% |
| Net profit | ₹13 Cr | ₹16 Cr | ₹18 Cr | ₹21 Cr | ₹30 Cr | ₹34 Cr | ₹37 Cr | ₹30 Cr |
| Net profit YoY | — | +130.8% | −45.0% | +19,154.5% | +131.0% | +104.4% | +104.1% | +43.8% |
| Net margin | 13.3% | 15.9% | 15.7% | 16.3% | 19.6% | 20.4% | 20.9% | 16.9% |
| EPS | ₹3.92 | ₹5.04 | ₹3.81 | ₹4.60 | ₹6.54 | ₹7.29 | ₹7.96 | ₹6.61 |
Senores Pharmaceuticals financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹14 Cr | ₹35 Cr | ₹215 Cr | ₹398 Cr |
| Operating profit | ₹1 Cr | ₹12 Cr | ₹25 Cr | ₹71 Cr |
| Net profit | ₹1 Cr | ₹8 Cr | ₹33 Cr | ₹58 Cr |
| EPS (₹) | ₹2.00 | ₹9.00 | ₹14.00 | ₹16.00 |
| Cash from operations | −₹10 Cr | −₹1 Cr | −₹20 Cr | −₹46 Cr |
| Total debt | ₹12 Cr | ₹30 Cr | ₹134 Cr | ₹162 Cr |
| Shareholders' equity | ₹37 Cr | ₹46 Cr | ₹204 Cr | ₹786 Cr |
Senores Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 45.77% | 45.78% | 45.80% | 45.80% | 45.82% | 45.82% |
| Foreign institutions | 4.17% | 3.67% | 4.28% | 3.35% | 3.64% | 6.62% |
| Domestic institutions | 9.65% | 9.51% | 8.61% | 9.31% | 9.61% | 9.77% |
| Non-institutions | 40.40% | 41.04% | 41.31% | 41.54% | 40.93% | 37.79% |
| Promoter shares pledged | — | — | — | 1.90% | 1.90% | 2.81% |
Senores Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Senores Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KOVAIKovai Medical Center & Hospital | ₹5,738.00 | −2.24% | +190.4% | ₹6,279 Cr | 25.7 | — |
| NEPHROPLUSNephrocare Health Services | ₹599.90 | −0.84% | — | ₹6,019 Cr | 74.1 | — |
| SPARCSun Pharma Advanced Research Company | ₹176.82 | −1.22% | +35.4% | ₹5,738 Cr | 3.7 | — |
| SENORESSenores Pharmaceuticals | ₹1,233.30 | +0.35% | +71.0% | ₹5,680 Cr | 46.7 | — |
| INNOVACAPInnova Captab | ₹983.60 | +0.57% | +17.9% | ₹5,629 Cr | 40 | — |
| FDCFDC | ₹339.20 | −0.24% | −22.1% | ₹5,523 Cr | — | — |
| IOLCPIOL Chemicals and Pharmaceuticals | ₹173.27 | −0.76% | +80.5% | ₹5,086 Cr | 36.9 | — |
Ask anything about Senores Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against SENORES's own history. Try: “Why has SENORES moved over the last three months?” · “Backtest a 50-day moving-average crossover on SENORES over five years” · “Compare SENORES with KOVAI on margins and valuation”
Frequently asked questions about Senores Pharmaceuticals
What is the share price of Senores Pharmaceuticals today?
Senores Pharmaceuticals (NSE: SENORES) last closed at ₹1,233.30 on 22 Oct 2026. Its 52-week high is ₹1,599.00 and its 52-week low is ₹706.00.
What is the market cap of Senores Pharmaceuticals?
Senores Pharmaceuticals' market capitalisation is ₹5,680 Cr (₹5,680 Cr) at the 22 Oct 2026 close, ranking 740th among the NSE companies Pivot tracks.
What is the P/E ratio of Senores Pharmaceuticals?
Senores Pharmaceuticals trades at a trailing P/E of 46.7. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 36.9.
What is the ROE and ROCE of Senores Pharmaceuticals?
Return on equity was 7.4% in FY25 and return on capital employed was 9.3% in FY25 (consolidated figures).
Is Senores Pharmaceuticals a debt-free company?
No. Senores Pharmaceuticals' debt-to-equity ratio was 0.39 in FY25, with total debt of ₹162 Cr.
What were Senores Pharmaceuticals' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Senores Pharmaceuticals reported revenue of ₹180 Cr, +38.3% year on year, and net profit of ₹30 Cr, +43.8% year on year.
How has Senores Pharmaceuticals stock performed over the last year?
Senores Pharmaceuticals' share price has risen 71.0% over the past year, −11.4% over three months and −11.6% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Senores Pharmaceuticals?
As of 30 Jun 2026: promoters 45.82%, foreign institutions 6.62%, domestic institutions 9.77%, non-institutions 37.79%. 2.81% of promoter shares were pledged.
Who are Senores Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Senores Pharmaceuticals by market cap are Kovai Medical Center & Hospital, Nephrocare Health Services, Sun Pharma Advanced Research Company, Innova Captab, FDC and IOL Chemicals and Pharmaceuticals.
Is Senores Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Senores Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SENORES against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text